Israel cannabis producer InterCure buying Better for $35 million

Herzliya, Israel-based cannabis producer InterCure is buying rival medical marijuana company Cann Pharmaceutical, also known as Better, for $35 million (44.4 million Canadian dollars) in stock.

InterCure described Better as a pioneering Israeli medical cannabis multinational operator.

The deal includes Better’s:

  • Unique cultivars.
  • Cultivation site.
  • Intellectual property.
  • Commercial operations inside and outside Israel.

The acquisition is expected to close in mid-2022.

InterCure said the acquisition will create “revenue synergies” worth an estimated 50 million Israeli new shekels ($15.7 million) in the upcoming year.

“InterCure and Better’s combined business operations are expected to create a new force in the international cannabis industry that will further accelerate our global expansion plans and opportunities and the consolidation process,” InterCure CEO Alex Rabinovitch said in a statement.

Growing is all about the lighting

Read our exclusive guide for strategies and tips from expert cultivators who have amassed decades of experience studying horticulture lighting. Curated by MJBizDaily.

Inside the MJBizDaily Lighting Buyers Guide:
  • Horticultural professionals debunk 8 common lighting myths in cannabis.
  • How cannabis extraction companies can reduce energy costs.
  • Why experts say the future of horticultural lighting is in LED technology.
  • Cannabis lighting Glossary of Terms.
  • Buyers checklist & more!

 

The company did not state which international markets Better operates in.

InterCure shares are traded on the Nasdaq (INCR), Toronto Stock Exchange (INCR.U) and Tel Aviv Stock Exchange (INCR).